Compare SRTA & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | KMDA |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Israel |
| Employees | 601 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.3M | 488.6M |
| IPO Year | N/A | 2013 |
| Metric | SRTA | KMDA |
|---|---|---|
| Price | $5.53 | $8.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.81 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 741.8K | 33.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.27 | $13.94 |
| Revenue Next Year | $8.52 | $9.84 |
| P/E Ratio | ★ $9.88 | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $6.50 |
| 52 Week High | $6.02 | $9.35 |
| Indicator | SRTA | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 57.92 |
| Support Level | $4.08 | $8.38 |
| Resistance Level | $5.99 | $8.60 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 93.89 | 96.74 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.